⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 29, 2026Journal of Nuclear Medicine

Should Molecular Subtype Influence the Interpretation of Serial 68 Ga-HER2 PET/CT During Neoadjuvant Therapy?

Kadri Altundağ

View at Publisher

Ask AI

Bookmark

Share

Abstract

TO THE EDITOR: I read with great interest the prospective study by Gao et al. demonstrating that serial 68Ga-HER2 PET/CT performed after 2 cycles of neoadjuvant therapy and before surgery predicts pathologic complete response (pCR) in human epidermal growth factor receptor 2 (HER2)–positive

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kadri Altundağ (2026) studied this question.

synapsesocial.com/papers/6ae585624c46c197bbab4145 https://doi.org/10.2967/jnumed.126.273659

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Abstract PS1-06-30: Predicting pathological response to neoadjuvant therapy in HER2-positive breast cancer by using 68Ga-HER2 PET/CT: a prospective studyCohort Study · 2026
2<sup>68</sup>Ga-HER2 PET/CT for Predicting Pathologic Response to Neoadjuvant Therapy at Early Treatment and Preoperative Stages in HER2-Positive Breast Cancer: A Prospective Study.Cohort Study · 2026
3A prospective single-center cohort study: integrating PET imaging and genomics to identify early biomarkers of response to dual-targeted PH neoadjuvant therapy in breast cancer2025
4[68Ga]Ga-HER2 Affibody PET/CT for early prediction of neoadjuvant therapy outcome in HER2-positive breast cancer: a preliminary reportOriginal Research · 2026
5Abstract PO5-01-05: An Open-label, Single-center Study Assessing the Efficacy of PH-based Regimen as Neoadjuvant Therapy for HER2-positive Early-stage Breast Cancer: Integrating Genomic Features and Functional Imaging2024

Clinical utility of molecular imaging in newly diagnosed metastatic breast cancer.2024
18F-FDG PET/CT for early prediction of pathological complete response in breast cancer neoadjuvant therapy: a retrospective analysis2024
Impact of HER2-targeted PET/CT imaging in patients with breast cancer and therapeutic response monitoring2024
Impact of PSMA PET/CT Staging on Long-Term Outcomes in Patients with Clinically Localized Prostate Cancer: Results of a Large Single-Center CohortJournal of Nuclear Medicine · 2026
Botulinum Toxin Plus Transdermal Scopolamine Reduces Salivary Gland Uptake in Patients Undergoing Tandem Radiopharmaceutical Therapy with [ 225 Ac]Ac- and [ 177 Lu]Lu-PSMA RadioligandsJournal of Nuclear Medicine · 2026

More from Journal of Nuclear Medicine